NeoGenomics, Inc. (NASDAQ:NEO)’s share price hit a new 52-week high on Friday . The stock traded as high as $33.55 and last traded at $33.40, with a volume of 98843 shares. The stock had previously closed at $32.99.

Several research analysts have commented on NEO shares. ValuEngine downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of NeoGenomics in a report on Tuesday, October 29th. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. First Analysis downgraded shares of NeoGenomics from a “strong-buy” rating to an “outperform” rating and increased their price objective for the company from $29.00 to $35.00 in a report on Thursday. Finally, Needham & Company LLC started coverage on shares of NeoGenomics in a report on Friday, January 3rd. They set a “buy” rating and a $14.00 price objective for the company. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $24.29.

The firm’s fifty day simple moving average is $29.24 and its 200 day simple moving average is $24.56. The firm has a market cap of $3.44 billion, a P/E ratio of 3,297.30 and a beta of 1.06. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.05 and a current ratio of 4.24.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, October 29th. The medical research company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The business had revenue of $104.70 million during the quarter, compared to the consensus estimate of $99.38 million. During the same quarter in the prior year, the firm earned $0.05 EPS. The business’s revenue was up 51.5% on a year-over-year basis. On average, equities research analysts predict that NeoGenomics, Inc. will post 0.19 earnings per share for the current year.

In related news, VP Jennifer Balliet sold 6,833 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $23.45, for a total value of $160,233.85. Following the sale, the vice president now directly owns 29,529 shares of the company’s stock, valued at approximately $692,455.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert J. Shovlin sold 70,473 shares of the stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $23.11, for a total transaction of $1,628,631.03. Following the completion of the sale, the insider now directly owns 251,914 shares in the company, valued at $5,821,732.54. The disclosure for this sale can be found here. Insiders have sold a total of 471,874 shares of company stock valued at $11,259,917 in the last three months. Insiders own 8.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its position in shares of NeoGenomics by 867.5% during the third quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock worth $74,000 after acquiring an additional 3,470 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in shares of NeoGenomics by 75.0% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock worth $87,000 after acquiring an additional 1,950 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of NeoGenomics during the fourth quarter worth approximately $96,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of NeoGenomics by 14.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,778 shares of the medical research company’s stock worth $110,000 after acquiring an additional 739 shares during the period. Finally, Sigma Planning Corp purchased a new position in shares of NeoGenomics during the third quarter worth approximately $201,000. 83.28% of the stock is currently owned by institutional investors.

About NeoGenomics (NASDAQ:NEO)

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Article: Current Ratio

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.